Late-Breaking Trials in axSpA and PsA Save
Dr. Janet Pope reports on late-breaking abstract LB09 (Rotation or Change of Biologic After TNF blocker treatment failure for axial Spondyloarthritis) and late-breaking abstract LB06 (AgAIN Study: First Head-to-Head Trial of Secukinumab vs. Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis Patients Reveals Better Efficacy Across Multiple Domains) presented at the 2025 ACR Convergence meeting in Chicago.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.